摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-氟苯基)-2-甲基丙酸 | 93748-19-7

中文名称
2-(4-氟苯基)-2-甲基丙酸
中文别名
——
英文名称
2-(4-fluorophenyl)-2-methylpropanoic acid
英文别名
——
2-(4-氟苯基)-2-甲基丙酸化学式
CAS
93748-19-7
化学式
C10H11FO2
mdl
MFCD11036916
分子量
182.195
InChiKey
IOSAIRIBZLAABD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    268.8±15.0 °C(Predicted)
  • 密度:
    1.175±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2916399090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:974c0aa8998ac7924b86465af86518d1
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-(4-Fluorophenyl)-2-methylpropanoic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-(4-Fluorophenyl)-2-methylpropanoic acid
CAS number: 93748-19-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11FO2
Molecular weight: 182.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(4-氟苯基)-2-甲基丙酸 在 lithium aluminium tetrahydride 、 bis(η3-allyl-μ-chloropalladium(II)) 、 (S,R)-revJosiphos 、 caesium carbonate 作用下, 以 四氢呋喃甲苯 为溶剂, 反应 20.0h, 生成 3-(cyclopropylmethyl)-7-(2-(4-fluorophenyl)-2-methylpropoxy)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine
    参考文献:
    名称:
    Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia
    摘要:
    Triazolopyridine ethers with mGlu(2) positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mG1u(2) PAMs for the treatment of schizophrenia and merit further preclinical investigation. (C) 2016 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2016.11.018
  • 作为产物:
    描述:
    、 sodium hydroxide 作用下, 以 甲醇 为溶剂, 反应 2.0h, 以86%的产率得到2-(4-氟苯基)-2-甲基丙酸
    参考文献:
    名称:
    一种α-(4-取代苯基)异丁酸的制备方法
    摘要:
    本发明涉及有机化学合成领域,公开了一种α‑(4‑取代苯基)异丁酸的制备方法。该方法是单取代苯与酰化剂2‑卤代异丁酰卤或异丁酰卤发生傅克酰基化反应、缩合反应、重排反应和水解酸化反应,最终制得α‑(4‑取代苯基)异丁酸成品。本发明提供的制备方法原料易得,毒性较小,重排反应的催化体系能够有效的促进重排反应的进行,所得产物的纯度和收率较高,整个制备方法简单,所用试剂安全,利于工业生产。
    公开号:
    CN105037059B
点击查看最新优质反应信息

文献信息

  • [EN] INDANE DERIVATIVES AS MGLUR7 MODULATORS<br/>[FR] DÉRIVÉS D'INDANE UTILISÉS COMME MODULATEURS DE MGLUR7
    申请人:TAKEDA PHARMACEUTICALS CO
    公开号:WO2017131221A1
    公开(公告)日:2017-08-03
    The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds of formula (I) are mGluR7 modulators.
    本发明提供了式(I)的化合物及其药学上可接受的盐,其中R1、R2、R3、R4a和R4b如规范中定义,其制备方法,含有它们的药物组合物以及它们在治疗中的用途。式(I)的化合物是mGluR7调节剂。
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    申请人:Bristol-Myers Squibb Company
    公开号:US20150232463A1
    公开(公告)日:2015-08-20
    The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    该披露通常涉及公式I、II、III和IV的化合物,包括用于治疗人类免疫缺陷病毒(HIV)感染的组合物和方法。该披露提供了HIV的新型抑制剂,包含这些化合物的药物组合物,以及在治疗HIV感染中使用这些化合物的方法。
  • Phenylene-bridged bis(benzimidazolium) (BBIm<sup>2+</sup>): a dicationic organic photoredox catalyst
    作者:Takuya Kodama、Maiko Kubo、Wataru Shinji、Kei Ohkubo、Mamoru Tobisu
    DOI:10.1039/d0sc03958f
    日期:——
    demonstrated to promote the photochemical decarboxylative hydroxylation and dimerisation of carboxylic acids. The catalytic activity of BBIm2+ was higher than that for a monocation analogue, suggesting that the dicationic nature of BBIm2+ plays a key role in these decarboxylative reactions. The rate constant for the decay of the triplet–triplet absorption of the excited BBIm2+ increased with increasing
    设计,合成并证明了由亚苯基桥联的双(苯并咪唑鎓)(BBIm 2+)组成的专用光氧化还原催化剂可促进羧酸的光化学脱羧羟基化和二聚。BBIm 2+的催化活性高于单阳离子类似物的催化活性,表明BBIm 2+的去离子性质在这些脱羧反应中起关键作用。被激发的BBIm 2+的三重态-三重态吸收的衰减速率常数随着具有饱和依赖性的羧酸根阴离子浓度的增加而增加,表明光诱导的电子转移发生在由BBIm的三重态激发态组成的离子对复合物中2+ 和羧酸根阴离子。
  • Palladium(II)-Catalyzed Directed Trifluoromethylthiolation of Unactivated C(sp<sup>3</sup>)–H Bonds
    作者:Heng-Ying Xiong、Tatiana Besset、Dominique Cahard、Xavier Pannecoucke
    DOI:10.1021/acs.joc.5b00505
    日期:2015.4.17
    by Pd-catalyzed C(sp3)–H bond functionalization was developed. Using a bidentate directing group, the direct and selective introduction of a SCF3 moiety was possible on a range of amides with remarkable selectivity for C(sp3)-centers with an electrophilic SCF3 source and pivalic acid as an additive. This work constitutes an example of the unactivated C(sp3)–SCF3 bond formation by C–H activation offering
    开发了钯催化的C(sp 3)–H键官能化的三氟甲基硫代脂肪酸衍生物的合成。使用双齿指导基团,可以在一系列具有亲电SCF 3源和新戊酸作为添加剂的C(sp 3)中心具有显着选择性的酰胺上,直接和选择性地引入SCF 3部分。这项工作构成了通过C–H激活形成未激活的C(sp 3)–SCF 3键的一个例子,为相关分子提供了新的途径。
  • Electrochemical Decarboxylative <i>N</i>-Alkylation of Heterocycles
    作者:Tao Sheng、Hai-Jun Zhang、Ming Shang、Chi He、Julien. C. Vantourout、Phil. S. Baran
    DOI:10.1021/acs.orglett.0c02799
    日期:2020.10.2
    An operationally simple method to employ nonactivated carboxylic acids as alkylating agents in the N-alkylation of heterocycles is reported through an electrochemically driven anodic decarboxylative process. A wide substrate scope across a range of heterocycles is demonstrated along with a series of applications that significantly reduce the step count required to access such medicinally relevant structures
    通过电化学驱动的阳极脱羧过程,报道了一种操作简单的方法,即在杂环的N-烷基化中使用未活化的羧酸作为烷基化剂。展示了一系列杂环的广泛底物范围以及一系列应用,这些应用显着减少了访问此类医学相关结构所需的步数。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐